Henry Schein (HSIC)
(Delayed Data from NSDQ)
$71.21 USD
-0.73 (-1.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.21 USD
-0.73 (-1.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth D Momentum B VGM
Zacks News
SmileDirectClub (SDC) Introduces Two New Water Flossers
by Zacks Equity Research
SmileDirectClub (SDC) launched the new Large Tank and Compact Water Flossers, currently available at Shop.SmileDirectClub.com, Amazon, Walmart and Walmart.com.
Breast Health Sales to Drive Hologic's (HOLX) Q4 Earnings
by Zacks Equity Research
The acquisition of Biotheranostics and the launch of new software are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the fourth quarter.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its fourth-quarter performance.
Here's Why You Should Hold on to Walgreens Boots (WBA) for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.
QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold
by Zacks Equity Research
QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Continued strong adoption of Invisalign Clear Aligners and iTero scanners is expected to contribute to Align Technology's (ALGN) third-quarter 2021 results.
Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.
ResMed (RMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).
Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study
by Zacks Equity Research
Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.
Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance
by Zacks Equity Research
According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.
LHC Group (LHCG) Reports Impressive Preliminary Q3 Revenues
by Zacks Equity Research
Growth in LHC Group's (LHCG) revenues in the third quarter is likely to have been boosted by continued strength in its home health and hospice services.
PerkinElmer's (PKI) New Deal to Improve Single-Cell Profiling
by Zacks Equity Research
PerkinElmer (PKI) partners with Honeycomb Biotechnologies to launch HIVE scRNAseq Solution, which can advance single-cell profiling.
Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.
HSIC or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.
Cardinal Health's (CAH) Unit Ties Up to Boost Diabetes Care
by Zacks Equity Research
Cardinal Health's (CAH) company, OptiFreight Logistics', recent collaboration with Journey Biosciences to help patients with respect to long-term diabetes care.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Allscripts' (MDRX) New AI-Based Offering to Improve Patient Care
by Zacks Equity Research
Allscripts' (MDRX) latest AI-based scheduling application is expected to provide improved patient care as well as increase operational efficiencies of the healthcare system.
Quest Diagnostics (DGX) Enhances Lab Experience With Facility
by Zacks Equity Research
Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.